261 related articles for article (PubMed ID: 37496990)
21. CEP55 promotes epithelial-mesenchymal transition in renal cell carcinoma through PI3K/AKT/mTOR pathway.
Chen H; Zhu D; Zheng Z; Cai Y; Chen Z; Xie W
Clin Transl Oncol; 2019 Jul; 21(7):939-949. PubMed ID: 30607788
[TBL] [Abstract][Full Text] [Related]
22. DKC1 serves as a potential prognostic biomarker for human clear cell renal cell carcinoma and promotes its proliferation, migration and invasion via the NF‑κB pathway.
Zhang M; Pan Y; Jiang R; Hou P; Shan H; Chen F; Jiang T; Bai J; Zheng J
Oncol Rep; 2018 Aug; 40(2):968-978. PubMed ID: 29901172
[TBL] [Abstract][Full Text] [Related]
23. VHL mutation-mediated SALL4 overexpression promotes tumorigenesis and vascularization of clear cell renal cell carcinoma via Akt/GSK-3β signaling.
Sun J; Tang Q; Gao Y; Zhang W; Zhao Z; Yang F; Hu X; Zhang D; Wang Y; Zhang H; Song B; Zhang B; Wang H
J Exp Clin Cancer Res; 2020 Jun; 39(1):104. PubMed ID: 32513235
[TBL] [Abstract][Full Text] [Related]
24. SCP phosphatases suppress renal cell carcinoma by stabilizing PML and inhibiting mTOR/HIF signaling.
Lin YC; Lu LT; Chen HY; Duan X; Lin X; Feng XH; Tang MJ; Chen RH
Cancer Res; 2014 Dec; 74(23):6935-46. PubMed ID: 25293974
[TBL] [Abstract][Full Text] [Related]
25. Forkhead Box M1 positively regulates UBE2C and protects glioma cells from autophagic death.
Guo L; Ding Z; Huang N; Huang Z; Zhang N; Xia Z
Cell Cycle; 2017 Sep; 16(18):1705-1718. PubMed ID: 28767320
[TBL] [Abstract][Full Text] [Related]
26. UBE2O promotes hepatocellular carcinoma cell proliferation and invasion by regulating the AMPKα2/mTOR pathway.
Shi Z; Liu R; Lu Q; Zeng Z; Liu Y; Zhao J; Liu X; Li L; Huang H; Yao Y; Huang D; Xu Q
Int J Med Sci; 2021; 18(16):3749-3758. PubMed ID: 34790050
[TBL] [Abstract][Full Text] [Related]
27. Aberrant MEK5 signalling promotes clear cell renal cell carcinoma development via mTOR activation.
Li F; Peng X; Zhou J; Chen Q; Chen Y
J Cancer Res Clin Oncol; 2022 Dec; 148(12):3257-3266. PubMed ID: 35713705
[TBL] [Abstract][Full Text] [Related]
28. C2orf40 inhibits metastasis and regulates chemo-resistance and radio-resistance of nasopharyngeal carcinoma cells by influencing cell cycle and activating the PI3K/AKT/mTOR signaling pathway.
Xie Z; Li W; Ai J; Xie J; Zhang X
J Transl Med; 2022 Jun; 20(1):264. PubMed ID: 35676661
[TBL] [Abstract][Full Text] [Related]
29. Formin-related protein 1 facilitates proliferation and aggressive phenotype of clear cell renal cell carcinoma through MAPK/MMP2 pathway.
Ma G; Zhang B; Fu S; Lu J; Zhang L; Shang P; Yue Z
Mol Cell Probes; 2023 Oct; 71():101921. PubMed ID: 37454877
[TBL] [Abstract][Full Text] [Related]
30. UBE2C promotes the progression of head and neck squamous cell carcinoma.
Jin Z; Zhao X; Cui L; Xu X; Zhao Y; Younai F; Messadi D; Hu S
Biochem Biophys Res Commun; 2020 Mar; 523(2):389-397. PubMed ID: 31870550
[TBL] [Abstract][Full Text] [Related]
31. Downregulation of CLDN7 due to promoter hypermethylation is associated with human clear cell renal cell carcinoma progression and poor prognosis.
Li Y; Gong Y; Ning X; Peng D; Liu L; He S; Gong K; Zhang C; Li X; Zhou L
J Exp Clin Cancer Res; 2018 Nov; 37(1):276. PubMed ID: 30428910
[TBL] [Abstract][Full Text] [Related]
32. STAT3-induced lncRNA HAGLROS overexpression contributes to the malignant progression of gastric cancer cells via mTOR signal-mediated inhibition of autophagy.
Chen JF; Wu P; Xia R; Yang J; Huo XY; Gu DY; Tang CJ; De W; Yang F
Mol Cancer; 2018 Jan; 17(1):6. PubMed ID: 29329543
[TBL] [Abstract][Full Text] [Related]
33. MicroRNA-99a induces G1-phase cell cycle arrest and suppresses tumorigenicity in renal cell carcinoma.
Cui L; Zhou H; Zhao H; Zhou Y; Xu R; Xu X; Zheng L; Xue Z; Xia W; Zhang B; Ding T; Cao Y; Tian Z; Shi Q; He X
BMC Cancer; 2012 Nov; 12():546. PubMed ID: 23173671
[TBL] [Abstract][Full Text] [Related]
34. TTI1 promotes non-small-cell lung cancer progression by regulating the mTOR signaling pathway.
Zhang LX; Yang X; Wu ZB; Liao ZM; Wang DG; Chen SW; Lu F; Wu YB; Zhu SQ
Cancer Sci; 2023 Mar; 114(3):855-869. PubMed ID: 36403197
[TBL] [Abstract][Full Text] [Related]
35. CMTM4 is frequently downregulated and functions as a tumour suppressor in clear cell renal cell carcinoma.
Li T; Cheng Y; Wang P; Wang W; Hu F; Mo X; Lv H; Xu T; Han W
J Exp Clin Cancer Res; 2015 Oct; 34():122. PubMed ID: 26474560
[TBL] [Abstract][Full Text] [Related]
36. An increase in long non-coding RNA PANDAR is associated with poor prognosis in clear cell renal cell carcinoma.
Xu Y; Tong Y; Zhu J; Lei Z; Wan L; Zhu X; Ye F; Xie L
BMC Cancer; 2017 May; 17(1):373. PubMed ID: 28545465
[TBL] [Abstract][Full Text] [Related]
37. Zic2 promotes tumor growth and metastasis via PAK4 in hepatocellular carcinoma.
Lu SX; Zhang CZ; Luo RZ; Wang CH; Liu LL; Fu J; Zhang L; Wang H; Xie D; Yun JP
Cancer Lett; 2017 Aug; 402():71-80. PubMed ID: 28577975
[TBL] [Abstract][Full Text] [Related]
38. Overexpression of FoxM1 is associated with tumor progression in patients with clear cell renal cell carcinoma.
Xue YJ; Xiao RH; Long DZ; Zou XF; Wang XN; Zhang GX; Yuan YH; Wu GQ; Yang J; Wu YT; Xu H; Liu FL; Liu M
J Transl Med; 2012 Sep; 10():200. PubMed ID: 23006512
[TBL] [Abstract][Full Text] [Related]
39. LINC01426 contributes to clear cell renal cell carcinoma progression by modulating CTBP1/miR-423-5p/FOXM1 axis via interacting with IGF2BP1.
Jiang Y; Zhang H; Li W; Yan Y; Yao X; Gu W
J Cell Physiol; 2021 Jan; 236(1):427-439. PubMed ID: 32583425
[TBL] [Abstract][Full Text] [Related]
40. The long non-coding RNA NNT-AS1 promotes clear cell renal cell carcinoma progression via regulation of the miR-137/ Y-box binding protein 1 axis.
Zhou Y; Zhang Z; Wo M; Xu W
Bioengineered; 2021 Dec; 12(1):8994-9005. PubMed ID: 34643163
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
